<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRIMIPRAMINE MALEATE</span><br/>(tri-mip'ra-meen)<br/><span class="topboxtradename">Surmontil<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">psychotherapeutic</span>; <span class="classification">tricyclic antidepressant</span><br/><b>Prototype: </b>Imipramine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 100 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Tricyclic antidepressant (TCA) pharmacologically similar to imipramine. Moderate anticholinergic and strong sedative effects;
         useful in depression associated with anxiety and sleep disturbances. Recent studies suggest strong, active H<sub>2</sub>-receptor antagonism is a characteristic of TCAs.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>More effective in alleviation of endogenous depression than other depressive states.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of major depression.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Peptic ulcer disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Prostatic hypertrophy; during recovery period after MI. Safety during pregnancy (category C) or lactation is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Schizophrenia, electroshock therapy, suicidal tendency; cardiovascular, liver, thyroid, kidney disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 75100 mg/d in divided doses, may increase gradually up to 300 mg/d if needed <span class="rdroute">PO Maintenance Dose</span> Usually 50150 mg/d<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 25 mg h.s., may increase q3d (max: 100 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to decrease gastric distress.</li>
<li>Store in tightly closed container at 15°30° C (59°86° F) unless otherwise specified.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Seizures, tremor, confusion, <span class="speceff-common">sedation</span>. <span class="typehead">Special Senses:</span> Blurred vision. <span class="typehead">CV:</span> Tachycardia, <span class="speceff-common">orthostatic hypotension,</span> hypertension. <span class="typehead">GI:</span> <span class="speceff-common">Xerostomia, constipation,</span> paralytic ileus. <span class="typehead">Urogenital:</span> <span class="speceff-common">Urinary retention</span>. <span class="typehead">Skin:</span> Photosensitivity, sweating. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease some antihypertensive response to <span class="classification">antihypertensives</span>; <span class="classification">cns depressants</span>, <b>alcohol,</b> <span class="classification">hypnotics</span>, <span class="classification">barbiturates</span>, <span class="classification">sedatives</span> potentiate CNS depression; may increase hypoprothrombinemic effect of <span class="classification">oral anticoagulants</span>; <b>ethchlorvynol</b> may cause transient delirium; with <b>levodopa</b>, <span class="classification">sympathomimetics</span> (e.g., <b>epinephrine,</b> <b>norepinephrine</b>), possibility of sympathetic hyperactivity with hypertension and hyperpyrexia; with <span class="classification">mao inhibitors</span>, possibility of severe reactions, toxic psychosis, cardiovascular instability; <b>methylphenidate increases plasma TCA levels;</b> <span class="classification">thyroid agents</span> may increase possibility of arrhythmias; <b>cimetidine</b> may increase plasma TCA levels. <span class="typehead">Herbal:</span> <b>Ginkgo</b> may decrease seizure threshold; <b>St. John's wort</b> may cause <b>serotonin</b> syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine and feces. <span class="typehead">Half-Life:</span> 9.1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess vital signs (BP and pulse rate) during adjustment period of tricyclic antidepressant (TCA) therapy. If BP falls more
            than 20 mm Hg or if there is a sudden increase in pulse rate, withhold medication and notify physician.
         </li>
<li>Orthostatic hypotension may be sufficiently severe to require protective assistance when patient is ambulating. Instruct patient
            to change position from recumbency to standing slowly and in stages.
         </li>
<li>Report signs of liver dysfunction: Yellow skin and sclerae, light-colored stools, pruritus, abdominal discomfort.</li>
<li>Report fine tremors, a distressing extrapyramidal adverse effect, to physician.</li>
<li>Monitor bowel elimination pattern and I&amp;O ratio. Severe constipation and urinary retention are potential problems, especially
            in older adults. Advise increased fluid intake to at least 1500 mL/d (if allowed).
         </li>
<li>Monitor patient carefully during initial drug therapy when therapeutic "lag period" may foster noncompliance.</li>
<li>Inspect oral membranes daily with high-dose therapy. Urge outpatient to report symptoms of stomatitis or xerostomia.</li>
<li>Regulate environmental temperature and patient's clothing carefully; drug may cause intolerance to heat or cold.</li>
<li>Excessive alcohol may potentiate TCA effects and increase the danger of overdosage or suicide attempt.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that your ability to perform tasks requiring alertness and skill may be impaired.</li>
<li>Do not use OTC drugs unless approved by physician.</li>
<li>Understand that the actions of both alcohol and trimipramine are increased when used together during therapy and for up to
            2 wk after the TCA is discontinued. Consult physician about safe amounts of alcohol, if any, that can be taken.
         </li>
<li>Be aware that the effects of barbiturates and other CNS depressants may also be enhanced by trimipramine.</li>
<li>Expect that therapeutic response will be delayed because TCAs have a "lag period" of 24 wk. Increased dosage
            does not shorten period but rather increases incidence of adverse reactions. Keep physician advised and do not interrupt therapy.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>